Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Core Insights - Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases [3] - The company will have its CEO, Warner Biddle, present at multiple upcoming healthcare conferences in September 2025 [1][2] Conference Details - Kyverna will present at the 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 11:00 a.m. ET [1] - The company will also participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 4:05 p.m. ET [1] - Additionally, Kyverna will be featured at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 11:00 a.m. ET [2] Company Pipeline - Kyverna's lead CAR T-cell therapy candidate, KYV-101, is in late-stage clinical development for stiff person syndrome and myasthenia gravis, with ongoing trials for lupus nephritis [3] - The company is also exploring other indications such as multiple sclerosis and rheumatoid arthritis through various trials [3] - Kyverna is developing next-generation CAR T-cell therapies in both autologous and allogeneic formats, aiming to expand into broader autoimmune indications [3]